MicroRNA‑652 inhibits the biological characteristics of esophageal squamous cell carcinoma by directly targeting fibroblast growth factor receptor 1

Zhen,Cheng; Huang,Jingshan; Lu,Jibin

doi:10.3892/etm.2019.8072

MicroRNA‑652 inhibits the biological characteristics of esophageal squamous cell carcinoma by directly targeting fibroblast growth factor receptor 1

Authors:
- Cheng Zhen
- Jingshan Huang
- Jibin Lu
View Affiliations

Affiliations: Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China
Published online on: October 1, 2019 https://doi.org/10.3892/etm.2019.8072
Pages: 4473-4480

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous studies have demonstrated that microRNAs (miRNAs) are dysregulated in esophageal squamous cell carcinoma (ESCC). Changes in miRNA expression may be associated with ESCC formation and progression. Therefore, the identification of ESCC‑associated miRNAs may facilitate the development of effective therapeutic approaches for patients with ESCC. Recently, miRNA‑652 (miR‑652) was recognized as a cancer‑associated miRNA in a number of different types of cancer. However, the expression status and roles of miR‑652 in ESCC as well as the molecular mechanisms modulated or altered by it remain largely unknown. In the present study, it was demonstrated that miR‑652 was downregulated in ESCC tissues and cell lines. Functional assays showed that upregulation of miR‑652 expression decreased proliferation and invasion of ESCC cells. Mechanistically, ﬁbroblast growth factor receptor 1 (FGFR1) was determined to be a direct target of miR‑652 in ESCC cells. Additionally, FGFR1 was upregulated in ESCC tissues, and the expression of FGFR1 was inversely correlated with miR‑652 expression. Furthermore, restoring FGFR1 expression abolished the suppressive effects of miR‑652 overexpression on the proliferation and invasion of ESCC cells. These findings demonstrated that miR‑652 inhibits the proliferation and invasion of ESCC cells by directly targeting FGFR1.

View Figures

View References

1	Cools-Lartigue J, Spicer J and Ferri LE: Current status of management of malignant disease: Current management of esophageal cancer. J Gastrointest Surg. 19:964–972. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Liu B, Jia Y, Cao Y, Wu S, Jiang H, Sun X, Ma J, Yin X, Mao A and Shang M: Overexpression of phosphoserine aminotransferase 1 (PSAT1) predicts poor prognosis and associates with tumor progression in human esophageal squamous cell carcinoma. Cell Physiol Biochem. 39:395–406. 2016. View Article : Google Scholar : PubMed/NCBI
4	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
5	Liu J, Xie X, Zhou C, Peng S, Rao D and Fu J: Which factors are associated with actual 5 year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg. 41:e7–e11. 2012. View Article : Google Scholar : PubMed/NCBI
6	Toh Y, Egashira A and Yamamoto M: Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg. 61:262–269. 2013. View Article : Google Scholar : PubMed/NCBI
7	Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 509:91–95. 2014. View Article : Google Scholar : PubMed/NCBI
8	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nature Rev Cancer. 6:857–866. 2006. View Article : Google Scholar
9	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
10	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
11	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 9:8522017. View Article : Google Scholar : PubMed/NCBI
12	Mei LL, Qiu YT, Zhang B and Shi ZZ: MicroRNAs in esophageal squamous cell carcinoma: Potential biomarkers and therapeutic targets. Cancer Biomark. 19:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
13	Askandar Iqbal M, Arora S, Prakasam G, Calin GA and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 17:300065–300067. 2018.
14	Yang S, Sun Z, Zhou Q, Wang W, Wang G, Song J, Li Z, Zhang Z, Chang Y, Xia K, et al: MicroRNAs, long noncoding RNAs, and circular RNAs: Potential tumor biomarkers and targets for colorectal cancer. Cancer Manag Res. 10:2249–2257. 2018. View Article : Google Scholar : PubMed/NCBI
15	Yuan HL, Wang T and Zhang KH: MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. OncoTargets Ther. 11:3891–3900. 2018. View Article : Google Scholar
16	Sharma N and Baruah MM: The microRNA signatures: Aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol. 21:126–144. 2018. View Article : Google Scholar : PubMed/NCBI
17	Li B, Xu WW, Han L, Chan KT, Tsao SW, Lee NPY, Law S, Xu LY, Li EM, Chan KW, et al: MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF. Oncogene. 36:3986–4000. 2017. View Article : Google Scholar : PubMed/NCBI
18	Lindner K, Eichelmann AK, Matuszcak C, Hussey DJ, Haier J and Hummel R: Complex epigenetic regulation of chemotherapy resistance and biohlogy in esophageal squamous cell carcinoma via microRNAs. Int J Mol Sci. 19:E4992018. View Article : Google Scholar : PubMed/NCBI
19	Mayne GC, Hussey DJ and Watson DI: MicroRNAs and esophageal cancer-implications for pathogenesis and therapy. Curr Pharm Des. 19:1211–1226. 2013. View Article : Google Scholar : PubMed/NCBI
20	Xue L, Nan J, Dong L, Zhang C, Li H, Na R, He H and Wang Y: Upregulated miR-483-5p expression as a prognostic biomarker for esophageal squamous cell carcinoma. Cancer Biomark. 19:193–197. 2017. View Article : Google Scholar : PubMed/NCBI
21	Islam F, Gopalan V, Law S, Tang JC, Chan KW and Lam AK: MiR-498 in esophageal squamous cell carcinoma: Clinicopathological impacts and functional interactions. Human Pathol. 62:141–151. 2017. View Article : Google Scholar
22	Sun X, Dongol S, Qiu C, Xu Y, Sun C, Zhang Z, Yang X, Zhang Q and Kong B: MiR-652 promotes tumor proliferation and metastasis by targeting RORA in endometrial cancer. Mol Cancer Res. 16:1927–1939. 2018. View Article : Google Scholar : PubMed/NCBI
23	Yang W, Zhou C, Luo M, Shi X, Li Y, Sun Z, Zhou F, Chen Z and He J: MiR-652-3p is upregulated in non-small cell lung cancer and promotes proliferation and metastasis by directly targeting Lgl1. Oncotarget. 7:16703–16715. 2016.PubMed/NCBI
24	Jiang Q, Lu X, Huang P, Gao C, Zhao X, Xing T, Li G, Bao S and Zheng H: Expression of miR-652-3p and effect on apoptosis and drug sensitivity in pediatric acute lymphoblastic leukemia. BioMed Res Int. 5:57246862018.
25	Deng S, Li X, Niu Y, Zhu S, Jin Y, Deng S, Chen J, Liu Y, He C, Yin T, et al: MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Oncotarget. 6:39661–39675. 2015. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Sugiura K, Ozawa S, Kitagawa Y, Ueda M and Kitajima M: Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 17:557–564. 2007.PubMed/NCBI
28	Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung DH, Shin SK, et al: Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget. 6:2562–2572. 2015.PubMed/NCBI
29	Song Q, Liu Y, Jiang D, Wang H, Huang J, Xu Y, Sujie A, Zeng H, Xu C and Hou Y: High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients. Oncotarget. 8:74539–74553. 2017.PubMed/NCBI
30	Wang D, Du L, Wang Z, Liu X, Qin Y, Wang Q, Yang Z, Yao Z, Shi M, Shang B, et al: Association of fibroblast growth factor receptor 1 gene amplification with poor survival in patients with esophageal squamous cell carcinoma. Oncotarget. 8:88857–88869. 2017.PubMed/NCBI
31	Chen B, Liu S, Gan L, Wang J, Hu B, Xu H, Tong R, Yang H, Cristina I, Xue J, et al: FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients. Cancer Biol Ther. 19:76–86. 2018. View Article : Google Scholar : PubMed/NCBI
32	Ma T, Zhao Y, Lu Q, Lu Y, Liu Z, Xue T and Shao Y: MicroRNA-30c functions as a tumor suppressor via targeting SNAI1 in esophageal squamous cell carcinoma. Biomed Pharmacothe. 98:680–686. 2018. View Article : Google Scholar
33	Qi B, Wang Y, Chen ZJ, Li XN, Qi Y, Yang Y, Cui GH, Guo HZ, Li WH and Zhao S: Down-regulation of miR-30a-3p/5p promotes esophageal squamous cell carcinoma cell proliferation by activating the Wnt signaling pathway. World J Gastroenterol. 23:7965–7977. 2017. View Article : Google Scholar : PubMed/NCBI
34	Cui XB, Peng H, Li RR, Mu JQ, Yang L, Li N, Liu CX, Hu JM, Li SG, Wei Y, et al: MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma. Oncotarget. 8:92454–92469. 2017. View Article : Google Scholar : PubMed/NCBI
35	Yang B, Xie R, Wu SN, Gao CC, Yang XZ and Zhou JF: MicroRNA-615-5p targets insulin-like growth factor 2 and exerts tumor-suppressing functions in human esophageal squamous cell carcinoma. Oncol Rep. 39:255–263. 2018.PubMed/NCBI
36	Zuo J, Zhu K, Wang Y and Yu Z: MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44. Mol Cell Biochem. 443:139–149. 2018. View Article : Google Scholar : PubMed/NCBI
37	Gao X, Xie Z, Wang Z, Cheng K, Liang K and Song Z: Overexpression of miR-191 predicts poor prognosis and promotes proliferation and invasion in esophageal squamous cell carcinoma. Yonsei Med J. 58:1101–1110. 2017. View Article : Google Scholar : PubMed/NCBI
38	Turner CA, Calvo N, Frost DO, Akil H and Watson SJ: The fibroblast growth factor system is downregulated following social defeat. Neurosci Lett. 430:147–150. 2008. View Article : Google Scholar : PubMed/NCBI
39	Schäfer MH, Lingohr P, Sträßer A, Lehnen NC, Braun M, Perner S, Höller T, Kristiansen G, Kalff JC and Gütgemann I: Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma. Human Pathol. 46:1488–1495. 2015. View Article : Google Scholar
40	Abdul-Maksoud RS, Shalaby SM, Elsayed WS and Elkady S: Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancer. Gene. 591:320–326. 2016. View Article : Google Scholar : PubMed/NCBI
41	Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W and Lu S: FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene. 27:5340–5354. 2018. View Article : Google Scholar
42	Cheng CL, Thike AA, Tan SY, Chua PJ, Bay BH and Tan PH: Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer. Breast Cancer Res Treat. 151:99–111. 2015. View Article : Google Scholar : PubMed/NCBI